Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma ( DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

被引：9
|
作者：
Casulo, Carla [1 ]
Santoro, Armando [2 ,3 ]
Ando, Kiyoshi [4 ]
Le Gouill, Steven [5 ]
Ruan, Jia [6 ]
Radford, John [7 ,8 ]
Arcaini, Luca [9 ,10 ]
Pinto, Antonello [11 ]
Bouabdallah, Reda [12 ]
Izutsu, Koji [13 ]
Rule, Simon [14 ]
Munoz, Javier [15 ]
Casadebaig, Marie-Laure [16 ]
Fox, Brian [17 ]
Rettby, Nils [16 ]
Dell'Aringa, Justine [17 ]
Delarue, Richard [16 ]
Newhall, Kathryn [17 ]
Czuczman, Myron [17 ]
Cartron, Guillaume [18 ]
机构：
[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA
[2] Humanitas Univ, Rozzano Milan, Italy
[3] Humanitas Clin & Res Ctr, Rozzano Milan, Italy
[4] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
[5] CHU Nantes, Nantes, France
[6] Weill Cornell Med, New York, NY USA
[7] Univ Manchester, Manchester, Lancs, England
[8] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[9] Fdn IRCCS Policlin San Matteo, Pavia, Italy
[10] Univ Pavia, Pavia, Italy
[11] Fdn G Pascale, Ist Nazl Tumori IRCCS, Naples, Italy
[12] Inst Paoli Calmettes, Marseille, France
[13] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[14] Univ Plymouth, Plymouth, Devon, England
[15] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[16] Celgene Int, Boudry, Switzerland
[17] Celgene Corp, Seattle, WA USA
[18] Ctr Hosp Univ Montpellier, Montpellier, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124102
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5320
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [2] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6
    Andorsky, David Jacob
    Boccia, Ralph V.
    Lash, Bradley Walter
    Vaidya, Rakhee
    Gandhi, Mitul
    Patel, Ameet
    Ibrahimi, Sami
    Madueno, Fernando Manuel Vargas
    Lee, Christina Y.
    Naik, Seema
    Haydu, J. Erika
    Fesler, Mark
    Osei-Bonsu, Kojo
    Conte, Kristin
    Doerr, Thomas
    Bai, Yang
    Sacchi, Mariana
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies
    Zhu, Min
    Conrado, Daniela
    Srinivasan, Kamal
    Brouwer-Visser, Jurriaan
    Yan, Hong
    Mohamed, Hesham
    Chaudhry, Aafia
    Ambati, Srikanth
    Harnisch, Lutz
    Davis, John D.
    BLOOD, 2023, 142
  • [5] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
    de Vos, Sven
    Reagan, Patrick M.
    Patel, Manish R.
    Saba, Nakhle S.
    Mortlock, Andrew
    Cerec, Virginie
    Munugalavadla, Veerendra
    Acar, Melih
    Nuttall, Barrett
    Jenkins, David
    White, Rafael
    Callahan, Megan
    Forcina, Alessandra
    Roschewski, Mark
    Flinn, Ian W.
    BLOOD, 2022, 140 : 6635 - 6637
  • [6] Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.
    Hawkes, Eliza Anne
    Manos, Kate
    Chong, Geoffrey
    Palmer, Jodie
    MacManus, Michael Patrick
    Keane, Colm
    Scott, Andrew Mark
    Shortt, Jake
    Ritchie, David
    Churilov, Leonid
    Johnston, Laura
    Witkowski, Tom
    Barraclough, Allison Anne
    Lee, Sze Ting
    Lin, Wendi
    Koldej, Rachel
    Khor, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis
    Li, Yin
    Li, Chunfan
    Lv, Kebing
    Wang, Shixuan
    Li, Fei
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e5 - e16
  • [8] An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Borchmann, P.
    Tam, C. S.
    Jaeger, U.
    McGuirk, J. P.
    Holte, H.
    Waller, E. K.
    Jaglowski, S. M.
    Bishop, M. R.
    Andreadis, C.
    Foley, S. R.
    Westin, J. R.
    Fleury, I.
    Ho, P. J.
    Mielke, S.
    Salles, G.
    Maziarz, R. T.
    Anak, Oe
    Pacaud, L. B.
    del Corral, C.
    Awasthi, R.
    Agoulnik, S.
    Tai, F.
    Schuster, S. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 36 - 37
  • [9] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Giri, Pratyush
    Patil, Sushrut
    Ratnasingam, Sumita
    Prince, H. Miles
    Milliken, Samuel
    Meijide, Javier Briones
    Coyle, Luke
    Van der Poel, Marjolein
    Mulroney, Carolyn M.
    Farooqui, Mohammed Z. H.
    Wong, Hansen
    Desai, Rajendra
    Zugmaier, Gerhard
    Mergen, Noemi
    Cannell, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
12345